MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Retractable Technologies Retained Earnings 2011-2026 | RVP
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Retractable Technologies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.7 M | 38.8 M | 46 M | 41.2 M | - | -33.9 M | -37 M | -35.7 M | -32 M | -28 M | -32.3 M | -30 M | -23.8 M | -19.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 46 M | -37 M | -9.21 M |
Quarterly Retained Earnings Retractable Technologies
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.3 M | 16 M | 16.1 M | 26.7 M | 23 M | 24.9 M | 39.2 M | 38.8 M | 38.9 M | 43 M | 47 M | 46 M | 50.4 M | 45 M | 48.7 M | 41.2 M | 20.3 M | 13.9 M | 8.29 M | -9.67 M | -9.67 M | -9.67 M | -9.67 M | -33.9 M | -33.9 M | -33.9 M | -33.9 M | -37 M | -37 M | -37 M | -37 M | -35.7 M | -35.7 M | -35.7 M | -35.7 M | -32 M | -32 M | -32 M | -32 M | -28.3 M | -28 M | -28 M | -28 M | -32.3 M | -32.3 M | -32.3 M | -32.3 M | -30 M | -30 M | -30 M | -30 M | -23.8 M | -23.8 M | -23.8 M | -23.8 M | -19.6 M | -19.6 M | -19.6 M | -19.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 50.4 M | -37 M | -8.89 M |
Retained Earnings of other stocks in the Medical instruments industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
382 K | - | - | $ 810 M |  USA |
 |
Becton, Dickinson and Company
BDX
|
16.6 B | $ 184.86 | 1.31 % | $ 53.2 B | USA |
 |
Baxter International
BAX
|
13.7 B | $ 21.74 | 1.85 % | $ 11.2 B | USA |
 |
Luminex Corporation
LMNX
|
83.8 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-120 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
-223 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
548 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
-11.9 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
2.13 B | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
1.13 B | - | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-250 M | $ 11.29 | -8.21 % | $ 228 M | USA |
 |
ICU Medical
ICUI
|
691 M | $ 155.85 | 4.08 % | $ 3.84 B | USA |
 |
Alcon
ALC
|
19.4 B | $ 82.21 | -1.21 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
-413 M | $ 32.79 | 1.27 % | $ 1.57 B | USA |
 |
electroCore
ECOR
|
-165 M | $ 6.16 | -0.16 % | $ 34 K | USA |
 |
Harvard Bioscience
HBIO
|
-146 M | $ 0.58 | -0.56 % | $ 24.6 M | USA |
 |
LeMaitre Vascular
LMAT
|
145 M | $ 92.55 | 0.75 % | $ 2.08 B | USA |
 |
AngioDynamics
ANGO
|
-429 M | $ 11.22 | 0.13 % | $ 458 M | USA |
 |
InfuSystem Holdings
INFU
|
-59.3 M | $ 7.9 | - | $ 163 M | USA |
 |
The Cooper Companies
COO
|
7.64 B | $ 84.11 | 0.51 % | $ 16.7 B | USA |
 |
Haemonetics Corporation
HAE
|
352 M | $ 61.61 | 1.55 % | $ 3.1 B | USA |
 |
iRhythm Technologies
IRTC
|
-803 M | $ 150.56 | -5.24 % | $ 4.82 B | USA |
 |
Isoray
ISR
|
-232 M | - | 0.03 % | $ 108 M | USA |
 |
Glaukos Corporation
GKOS
|
-599 M | $ 119.69 | 2.21 % | $ 5.8 B | USA |
 |
Repro Med Systems
KRMD
|
-23.3 M | $ 4.72 | 0.64 % | $ 215 M | USA |
 |
OraSure Technologies
OSUR
|
-103 M | $ 2.76 | -2.47 % | $ 205 M | USA |
 |
Masimo Corporation
MASI
|
1.49 B | $ 175.38 | 0.03 % | $ 9.35 B | USA |
 |
Intuitive Surgical
ISRG
|
7.01 B | $ 504.2 | 0.93 % | $ 180 B | USA |
 |
Merit Medical Systems
MMSI
|
696 M | $ 82.25 | 0.5 % | $ 4.79 B | USA |
 |
Microbot Medical
MBOT
|
-79.5 M | $ 2.07 | -3.95 % | $ 21.1 M |  Israel |
 |
Nephros
NEPH
|
-144 M | $ 4.14 | 6.43 % | $ 43 M | USA |
 |
NeuroMetrix
NURO
|
-218 M | - | 5.05 % | $ 9.02 M | USA |
 |
Milestone Scientific
MLSS
|
-128 M | $ 0.26 | -2.04 % | $ 20.7 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
-835 M | $ 12.63 | 0.88 % | $ 2.57 B | USA |
 |
Envista Holdings Corporation
NVST
|
-440 M | $ 29.16 | 1.53 % | $ 4.9 B | USA |
 |
Pro-Dex
PDEX
|
35.9 M | $ 39.55 | 1.41 % | $ 130 M | USA |
 |
Pulse Biosciences
PLSE
|
-463 M | $ 21.98 | -12.38 % | $ 1.48 B | USA |
 |
Predictive Oncology
POAI
|
-180 M | - | - | $ 31.1 M | USA |
 |
Stereotaxis
STXS
|
-538 M | $ 2.08 | -0.24 % | $ 168 M | USA |
 |
Repligen Corporation
RGEN
|
433 M | $ 136.76 | -0.34 % | $ 7.62 M | USA |
 |
ResMed
RMD
|
3.61 B | $ 258.04 | 0.68 % | $ 37.7 B | USA |
 |
BioLife Solutions
BLFS
|
-335 M | $ 23.17 | -0.26 % | $ 1.07 B | USA |
 |
STERIS plc
STE
|
2.48 B | $ 250.32 | -0.34 % | $ 24.7 B | USA |
 |
STAAR Surgical Company
STAA
|
-67.6 M | $ 17.65 | -1.29 % | $ 867 M | USA |
 |
Teleflex Incorporated
TFX
|
4.12 B | $ 115.88 | 3.65 % | $ 5.43 B | USA |
 |
Utah Medical Products
UTMD
|
138 M | $ 67.96 | 2.09 % | $ 247 M | USA |
 |
West Pharmaceutical Services
WST
|
4.37 B | $ 241.54 | -0.94 % | $ 17.5 B | USA |